A new endoscopically implantable device (satisphere) for treatment of obesity - Efficacy, safety, and metabolic effects on glucose, insulin, and GLP-1 Levels

Obesity Surgery

Volumn 23, Issue 11, 2013, Pages 1727-1733

  Sauer, Nina ^a   Rösch, Thomas ^a   Pezold, Jennifer ^a   Reining, Franziska ^a   Anders, Mario ^a   Groth, Stefan ^a   Schachschal, Guido ^a   Mann, Oliver ^a   Aberle, Jens ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

EndoSphere; GLP 1; Obesity; Weight Loss

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEVICE REMOVAL; ENDOSCOPICALLY IMPLANTABLE DEVICE; FEASIBILITY STUDY; FEMALE; GLUCOSE ABSORPTION; HEMICOLECTOMY; HUMAN; IATROGENIC DISEASE; INSULIN RELEASE; INTENTION TO TREAT ANALYSIS; INTESTINE ANASTOMOSIS; MALE; OBESITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN SECRETION; RANDOMIZED CONTROLLED TRIAL; SURGICAL EQUIPMENT; WEIGHT REDUCTION;

ADULT; BLOOD GLUCOSE; DEVICE REMOVAL; DUODENUM; EATING; ENDOSCOPY, GASTROINTESTINAL; EQUIPMENT DESIGN; FEASIBILITY STUDIES; FEMALE; FOREIGN-BODY MIGRATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; INSULIN; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; OBESITY; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84885483616     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-013-1005-0     Document Type: Article

References (25)

1. Wolfenstetter SB. Future direct and indirect costs of obesity and the influence of gaining weight: Results from the MONICA/KORA cohort studies, 1995-2005. Econ Hum Biol. 2012;10(2):127-38. doi: 10.1016/j.ehb.2011.08.008. Epub 2011 Sep 3.
2. von Lengerke T, Krauth C. Economic costs of adult obesity: a review of recent European studies with a focus on subgroup-specific costs. Maturitas. 2011;3:220-9. Epub 2011 May 18.
3. Schroeder R, Garrison Jr JM, Johnson MS. Treatment of adult obesity with bariatric surgery. Am Fam Physician. 2011;84(7):805-14.
4. Fischer L, Hildebrandt C, Bruckner T, et al. Excessive weight loss after sleeve gastrectomy: a systematic review. Obes Surg. 2012;22(5):721-31.
5. DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med. 2007;356(21):2176-83.
6. Ismail-Beigi F. Clinical practice. Glycemic management of type 2 diabetes mellitus. N Engl J Med. 2012;366(14):1319-27.
7. Swidnicka-Siergiejko A, Wróblewski E, Andrzej D. Endoscopic treatment of obesity. Can J Gastroenterol. 2011;25(11):627-33.
8. Tsmesmeli N, Coumaros D. Review of endoscopic devices for weight reduction: old and new balloons and implantable devices. Endoscopy. 2008;41:1802-9.
9. Fernandes M, Atallah AN, Soares BG, et al. Intragastric balloon for obesity. Cochrane Database Syst Rev. 2007;1, CD004931.
10. Gersin KS, Rothstein RI, Rosenthal RJ, et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71(6):976-82. Epub 2010 Mar 20.
11. Tarnoff M, Rodriguez L, Escalona A, et al. Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery. Surg Endosc. 2009;23(3):650-6. Epub 2008 Dec 6.
12. Rodriguez L, Reyes E, Fagalde P, et al. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther. 2009;11(11):725-32.
13. Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the EndoBarrier Gastrointestinal Liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251(2):236-43.
14. Deacon CF, Ahrén B. Physiology of incretins in health and disease. Rev Diabet Stud. 2011;8:293-306. Epub 2011 Nov 10.
15. Karras S, Goulis DG, Mintziori G, et al. The effects of incretins on energy homeostasis: physiology and implications for the treatment of type 2 diabetes mellitus and obesity. Curr Vasc Pharmacol. 2012;10(6):781-91.
16. Peters KR. Liraglutide for the treatment of type 2 diabetes: a clinical update. Am J Ther. 2013;20(2):178-88. doi: 10.1097/MJT.0b013e3182204c16.
17. Shyangdan DS, Royle P, Clar C, et al. Glucagon-like peptide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2011;10, CD006423.
18. Vilsbøll T, Christensen M, Junker AE, et al. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012;344:d7771.
19. Familiari P, Costamagna G, Bléro D, et al. Transoral gastroplasty for morbid obesity: a multicenter trial with a 1-year outcome. Gastrointest Endosc. 2011;74(6):1248-58.
20. Kumar N, Thompson CC. Endoscopic solutions for weight loss. Curr Opin Gastroenterol. 2011;27(5):407-11.
21. Ramhamadany EM, Fowler J, Baird IM. Effect of the gastric balloon versus sham procedure on weight loss in obese subjects. Gut. 1989;30(8):1054-7.
22. Holst JJ, Deacon CF, Vilsbøll T, et al. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med. 2008;14(4):161-8. Epub 2008 Mar 18.
23. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-705.
24. Beglinger C, Degen L. Gastrointestinal satiety signals in humans - physiologic roles for GLP-1 and PYY. Physiol Behav. 2006;4:460-4. Epub 2006 Jul 7.
25. Vollmer K, Holst JJ, Baller B, et al. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes. 2008;57(3):678-87. Epub 2007 Dec 5.